C11625: Markers to Differentiate between ER Subtypes, Predict Treatment Outcome and Risk of Reoccurrence in Breast Cancer
Value Proposition: - 40 loci have been validated in an independent dataset. - This technology may reveal important biological differences in the epigenome between breast cancer subtypes. - These markers may provide ancillary clinical diagnostic, prognostic and predictive tools. - This technology may be developed to detect methylated genes in various human samples obtained from serum, tissue, plasma, nipple aspirate fluid, fine needle aspirates, ductal lavage, ductoscopy, etc.
Technical Details:
JHU inventors performed a genome-wide methylation analysis on 103 primary invasive breast cancers and 21 normal breast samples and identified 40 loci showing differential methylation specific to either ER-positive or ER-negative tumors. These 40 loci were validated in silico using an independent methylome dataset from The Cancer Genome Atlas (TCGA). Additionally, inventors have also identified 100 methylated loci that were significantly associated with disease progression.
Looking for Partners:
This technology may be further developed to devise a test for breast cancer to differentiate between ER subtypes, predict response to therapy and risk of reoccurrence.
Publications/Associated Cases:
Fackler MJ, et. al. GENOME-WIDE METHYLATION ANALYSIS IDENTIFIES GENES SPECIFIC TO BREAST CANCER HORMONE RECEPTOR STATUS AND RISK OF RECURRENCE. Cancer Res. 2011 Aug 8. PMID: 21825015.
